Invivo Partners

Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology.

Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions.

Gyala Therapeutics is dedicated to developing innovative CAR-T therapies aimed at treating hematological malignancies, such as leukemia and B cell lymphomas. The company utilizes a gene therapy approach that involves extracting T lymphocytes, a type of white blood cell crucial for immune responses, from the patient through a process called apheresis. These cells are then genetically modified to express a receptor that specifically targets tumor cells. Once reintroduced into the patient's body, the modified T cells are designed to recognize and attack cancerous cells effectively. Gyala Therapeutics' focus on this advanced form of treatment positions it at the forefront of cancer therapeutics, offering new hope to patients battling critical diseases.

EsoBiotec is a Belgian biotechnology company dedicated to the discovery and development of novel cancer therapies. The firm focuses on empowering the human body to combat cancer through in vivo cell engineering. By creating innovative immunotherapies, EsoBiotec aims to provide cost-effective drugs and therapeutics that enhance accessibility, ensuring that patients can receive essential cancer treatments at lower costs.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Atekka is an insurance company focused on providing protection against agricultural risks. By integrating technical and technological innovations, Atekka develops tailored insurance products designed to support the agricultural sector. The company collaborates with cooperatives and farmers to offer customized solutions that help safeguard farms against various calamities.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

Integra Therapeutics is focused on advancing gene editing technologies to address various diseases. The company is developing innovative gene writing tools that aim to enhance the effectiveness of gene therapy. By combining the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in the field of gene editing. This approach allows scientists to introduce DNA into a genome using sequence-specific DNA binding proteins, thereby facilitating the development of targeted gene therapies that meet the specific needs of patients.

Telomere Therapeutics specializes in gene therapy focused on telomerase gene expression to address age-related diseases. The company's innovative approach utilizes an adenoviral vector to deliver the telomerase reverse transcriptase (TERT) gene, facilitating the treatment of conditions such as idiopathic pulmonary fibrosis, aplastic anemia, and dyskeratosis congenita. By enhancing telomerase activity, Telomere Therapeutics aims to improve cellular health and combat the effects of aging-related diseases, contributing to advancements in regenerative medicine.

MiiMOSA is a crowdfunding platform focused on the agriculture and food sectors. It provides an alternative financing solution that allows project developers to secure funding quickly and easily from a community of contributors. The platform enables various projects in the agriculture industry to receive financial support through contributions, which can also come in the form of product donations such as cheese, yogurt, whiskey, and ice cream. By offering a customized space for project creators, MiiMOSA facilitates collective financial backing from the general public for initiatives that resonate with their interests in the food and agriculture domains.

Telomere Therapeutics specializes in gene therapy focused on telomerase gene expression to address age-related diseases. The company's innovative approach utilizes an adenoviral vector to deliver the telomerase reverse transcriptase (TERT) gene, facilitating the treatment of conditions such as idiopathic pulmonary fibrosis, aplastic anemia, and dyskeratosis congenita. By enhancing telomerase activity, Telomere Therapeutics aims to improve cellular health and combat the effects of aging-related diseases, contributing to advancements in regenerative medicine.

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Telum Therapeutics is a biotechnology company focused on developing innovative treatments for infectious diseases. The company aims to address the growing issue of antibiotic resistance by providing alternatives to traditional chemical antibiotics. Utilizing lytic enzymes derived from bacteriophages, Telum Therapeutics creates therapies that target bacteria with immutable characteristics and offer rapid modes of action. This approach enables healthcare providers to deliver effective treatments to patients facing multi-resistant bacterial infections.

Gyala Therapeutics is dedicated to developing innovative CAR-T therapies aimed at treating hematological malignancies, such as leukemia and B cell lymphomas. The company utilizes a gene therapy approach that involves extracting T lymphocytes, a type of white blood cell crucial for immune responses, from the patient through a process called apheresis. These cells are then genetically modified to express a receptor that specifically targets tumor cells. Once reintroduced into the patient's body, the modified T cells are designed to recognize and attack cancerous cells effectively. Gyala Therapeutics' focus on this advanced form of treatment positions it at the forefront of cancer therapeutics, offering new hope to patients battling critical diseases.

Pulmobiotics is a pre-clinical life sciences company based in Barcelona, Spain, focused on developing innovative treatments and vaccines for lung diseases. The company utilizes synthetic biology to create attenuated lung bacteria that can expose antigens or deliver therapeutic agents directly in the lungs. This method allows for controlled, localized, and continuous delivery of treatment, specifically targeting the lungs to address various breathing-related issues. By developing novel antigens and vaccines, Pulmobiotics aims to improve the management and cure of human lung illnesses.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.